Oncotelic Therapeutics, Inc. (OTLC)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 12.99 Million USD | 15.46% |
| 2022 | 11.25 Million USD | 25.17% |
| 2021 | 8.99 Million USD | 65.63% |
| 2020 | 5.42 Million USD | 261.65% |
| 2019 | 1.5 Million USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | -100.0% |
| 2003 | 155 Thousand USD | 0.0% |
| 2002 | - USD | -100.0% |
| 2001 | 712.32 Thousand USD | 0.0% |
| 2000 | - USD | -100.0% |
| 1999 | 951.51 Thousand USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| 1995 | - USD | 0.0% |
| 1994 | - USD | 0.0% |
| 1993 | - USD | 0.0% |
| 1992 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 13.31 Million USD | 2.44% |
| 2024 Q2 | 13 Million USD | -2.36% |
| 2023 Q1 | 11.86 Million USD | 5.36% |
| 2023 FY | 12.99 Million USD | 15.46% |
| 2023 Q4 | 12.99 Million USD | 4.96% |
| 2023 Q3 | 12.38 Million USD | 2.05% |
| 2023 Q2 | 12.13 Million USD | 2.31% |
| 2022 Q1 | 10.3 Million USD | 14.54% |
| 2022 Q4 | 11.25 Million USD | 11.66% |
| 2022 FY | 11.25 Million USD | 25.17% |
| 2022 Q2 | 9.8 Million USD | -4.84% |
| 2022 Q3 | 10.08 Million USD | 2.85% |
| 2021 Q2 | 7.02 Million USD | 9.1% |
| 2021 Q1 | 6.44 Million USD | 18.64% |
| 2021 FY | 8.99 Million USD | 65.63% |
| 2021 Q3 | 7.34 Million USD | 4.48% |
| 2021 Q4 | 8.99 Million USD | 22.47% |
| 2020 Q4 | 5.42 Million USD | 79.66% |
| 2020 Q1 | 2.89 Million USD | 92.72% |
| 2020 Q2 | 2.47 Million USD | -14.58% |
| 2020 Q3 | 3.02 Million USD | 22.28% |
| 2020 FY | 5.42 Million USD | 261.65% |
| 2019 Q3 | 488.33 Thousand USD | 114.25% |
| 2019 Q2 | 227.92 Thousand USD | 314.41% |
| 2019 FY | 1.5 Million USD | 0.0% |
| 2019 Q4 | 1.5 Million USD | 207.46% |
| 2019 Q1 | 55 Thousand USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 FY | - USD | -100.0% |
| 2004 Q1 | - USD | -100.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 FY | 155 Thousand USD | 0.0% |
| 2003 Q4 | 155 Thousand USD | -73.64% |
| 2003 Q3 | 588 Thousand USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2002 Q1 | - USD | -100.0% |
| 2002 Q3 | 593 Thousand USD | 1.89% |
| 2002 Q2 | 582 Thousand USD | 0.0% |
| 2002 FY | - USD | -100.0% |
| 2002 Q4 | - USD | -100.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 FY | 712.32 Thousand USD | 0.0% |
| 2001 Q4 | 712.32 Thousand USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2000 Q1 | - USD | -100.0% |
| 2000 Q3 | 825 Thousand USD | 2.74% |
| 2000 Q4 | - USD | -100.0% |
| 2000 Q2 | 803 Thousand USD | 0.0% |
| 2000 FY | - USD | -100.0% |
| 1999 FY | 951.51 Thousand USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 Q4 | 951.51 Thousand USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| 1996 Q1 | - USD | 0.0% |
| 1995 Q2 | - USD | 0.0% |
| 1995 Q1 | - USD | 0.0% |
| 1995 Q4 | - USD | 0.0% |
| 1995 FY | - USD | 0.0% |
| 1994 Q2 | - USD | 0.0% |
| 1994 Q4 | - USD | 0.0% |
| 1994 FY | - USD | 0.0% |
| 1993 Q3 | 100 Thousand USD | 0.0% |
| 1993 FY | - USD | 0.0% |
| 1993 Q4 | - USD | -100.0% |
| 1992 FY | - USD | 0.0% |
| 1992 Q4 | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 68.456% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -215.311% |
| SQZ Biotechnologies Company | 27.47 Million USD | 52.688% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 70.034% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 56.338% |
| Mesoblast Limited | 118.7 Million USD | 89.051% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -1270.599% |
| Genus plc | 233.1 Million USD | 94.424% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -343.525% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -867.338% |
| Marizyme, Inc. | 18.71 Million USD | 30.562% |
| ContraFect Corporation | 2.88 Million USD | -351.128% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -1632.933% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -9492.799% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -798.626% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -458.781% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -129.696% |
| MultiCell Technologies, Inc. | 202.58 USD | -6415634.525% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 77.392% |
| EV Biologics, Inc. | 1.49 Million USD | -769.509% |
| Q BioMed Inc. | 4.1 Million USD | -216.23% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 60.735% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -1962.763% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -958.076% |
| Biomind Labs Inc. | 735.54 Thousand USD | -1666.996% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 92.424% |
| Skye Bioscience, Inc. | 4.61 Million USD | -181.609% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -1363.52% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -9083.987% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -121.373% |
| IMV Inc. | 28.88 Million USD | 55.003% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -50434.605% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -475.501% |
| GB Sciences, Inc. | 1.75 Million USD | -638.757% |
| Alpha Cognition Inc. | 1.22 Million USD | -965.003% |
| HST Global, Inc. | 98.31 Thousand USD | -13119.21% |
| CSL Limited | 12.18 Billion USD | 99.893% |
| Halberd Corporation | 150 Thousand USD | -8564.663% |
| Enzolytics Inc. | 996.33 Thousand USD | -1204.476% |
| Resverlogix Corp. | 6.49 Million USD | -100.231% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -2621.884% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -4985.055% |
| argenx SE | 20 Million USD | 35.015% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 71.473% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -379.824% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -127009.976% |
| Genscript Biotech Corporation | 417.73 Million USD | 96.889% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -6378.544% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -442.056% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -5568.341% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 80.786% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -329.484% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -3513.187% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 36.064% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -8643.118% |
| BioStem Technologies, Inc. | 4.71 Million USD | -175.862% |
| ONE Bio Corp. | 19.71 Million USD | 34.076% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -5095.016% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -5125.553% |
| Agentix Corp. | 50 Thousand USD | -25893.99% |
| LadRx Corporation | 33.6 Thousand USD | -38574.627% |
| Cell Source, Inc. | 9.25 Million USD | -40.445% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -1618.715% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -1618.715% |
| NovAccess Global Inc. | 2.19 Million USD | -490.805% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -83.76% |
| Itoco Inc. | 228.37 Thousand USD | -5591.026% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -6060.443% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -160.827% |
| Kadimastem Ltd | 891.22 Thousand USD | -1358.328% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -3134.298% |
| CytoDyn Inc. | 30.07 Million USD | 56.786% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -2583.755% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -3593.934% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -66.203% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -10509.792% |
| Rebus Holdings, Inc. | 310 Thousand USD | -4092.579% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -174.471% |
| International Stem Cell Corporation | 4.17 Million USD | -211.082% |
| Bioxytran, Inc. | 1.92 Million USD | -575.169% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -20724.179% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -495.946% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -56.289% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -51.392% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -735.562% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -4749.625% |
| Neutra Corp. | 54.15 Thousand USD | -23899.178% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -610.218% |
| PureTech Health plc | 25.51 Million USD | 49.055% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -961.65% |
| IXICO plc | 472.02 Thousand USD | -2653.466% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 16.154% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 79.126% |
| CSL Limited | 12.18 Billion USD | 99.893% |
| Cellectis S.A. | 92.77 Million USD | 85.991% |